Tomographic ultrasound developer Delphinus Medical Technologies has received $39.5 million in venture capital funding.
Led by Venture Investors, the funding round included new investment from Hopen Life Science Ventures and Waycross Ventures, along with current investors Arboretum Ventures, Beringea, and North Coast Technology Investors, according to Delphinus.
The company plans to use the money for regulatory and marketing efforts for its SoftVue whole-breast ultrasound system, an adjunct breast cancer screening modality for women with dense breasts. The device uses a circular ultrasound transducer that produces cross-sectional ultrasound slices through the entire volume of breast tissue.
Delphinus plans to launch a multisite clinical study to support a premarket approval (PMA) application for supplemental screening of women with dense breast tissue. The study will compare SoftVue with digital mammography and will include 10,000 women in eight centers around the U.S., the firm said.
